This makes many dice rolling at the same time

Alstom, the last in the CAC 40, continues on its cloud. The very good home made to the large American contract announced yesterday is 4.7 rising from its course since he joined the Parisian index July 31 (the index itself has gained only 1), and 49 a rising since the beginning of the year (which in fact the greatest ACC!). It is true that the construction of a boiler coal "clean" in a country like the United States, also hungry for electricity than polluter when it produced, well summarizes the two vectors energy and environment who maintain the dynamics of the French group. It also confirmed that Alstom has managed the most delicate market transition, value of rollover status, after having been near bankruptcy, the value of growth. In the light of the very generous valuation ratios and very favourable analysts consensus enjoyed by Alstom can even ask if it is not the subject of overconfidence. At 21 times the annual profits is expected next March, course builds more than of Air Liquide, a company that displays one of the most creative risk/growth combinations of value for over a century, and which involved it also global needs related to energy and the environment. In any case it is a level which implies no bad surprises.

The conjecture of Plavix

The fellows trust too Sanofi-aventis While in a New York Court plays a new decisive episode in the future to the United States of Plavix, its best-selling medicine, the course of the pharmaceutical group is evidence of a great resilience. Of course, it was shaken since American prosecutors have been flying shrapnel the non-aggression agreement with the Apotex génériqueur. But a decline of 7.5 on average six months previous East without common measure with, for example, that experienced by EADS for a comparable case. The volatility of Sanofi-Aventis is rather less than what it was less dramatic moments of the Plavix drama which lasts four years. A majority of analysts have even seized the opportunity to resume the reasoning of the more confident. Written off of Plavix, Sanofi-Aventis would retain profits growth prospects than the average of its sector. Draw a line on the American market would revise down previous course objectives, but the recent downturn in the title would have accentuated his haircut on his peers and would open a window of opportunity. As always this kind of speculation is loop with an ultimate assumption, namely that make the authorization to market in the United States the Accomplia, obesity treatment developed by Sanofi-Aventis, forget the Plavix. This makes many dice rolling at the same time.

A cruel clearly

The summer should be a challenging season for TUI, the first European operator of the tourism. Conversely, the German group offers a show where the confusion the dispute to underperformance. That very depressed during this very disputed member of the DAX 30 index must its small rebounds to rumours, unsubstantiated, departure of its Director General said already long. So, this is not tourism, poor conditions for everyone, which is a problem. Comparison of TUI with the main European values of the sector proposed by the Group's Web site was not updated for five months! And for cause, it highlights cruel evidence: the title continues to sink since TUI strengthened last year his division shipping with Canadian CP Ships, which undergoes integration costs after paying it the price today fort. The initiative has revealed how the ex-Preussag, that of some believed become a "pure player" leisure time under its new name, had retained its culture of conglomerate and is complaisait in the juxtaposition of multiple incoherent trades. Damage that the only shareholders represented on the Supervisory Board are two Spanish groups, partners of the hotel, but activity, 10 of the capital, is facing not enough to counterbalance.